PSTV
Plus Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Plus Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
No changes.
No changes.
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Cerenome, Inc.
1.30
−0.41 · −23.74%
post 1.25 −4.15%
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for Plus Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for Plus Therapeutics, Inc..
Tall tick = annual report · Source: EDGAR
−92.69%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.3M | 48.39% | −87.44% |
| BlackRockindex-like | $419,446 | 15.24% | −94.60% |
| Geodeindex-like | $332,941 | 12.10% | −96.22% |
| Vanguard Fiduciary Trustindex-like | $161,113 | 5.85% | −96.83% |
| Ashton Thomas Private Wealth | $149,917 | 5.45% | +4.23% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.3M | 48.39% | −87.44% |
| BlackRockindex-like | $419,446 | 15.24% | −94.60% |
| Geodeindex-like | $332,941 | 12.10% | −96.22% |
| Vanguard Fiduciary Trustindex-like | $161,113 | 5.85% | −96.83% |
| Ashton Thomas Private Wealth | $149,917 | 5.45% | +4.23% |